Literature DB >> 21900865

Synthesis and structural characterization of 1-[2-(5-nitro-1H-indol-2-yl)phenyl]methylpyridinium chloride.

John B Bremner1, Siritron Samosorn, Brian W Skelton, Allan H White.   

Abstract

In the course of studies on hybrid antibacterials incorporating 2-aryl-5-nitro-1H-indole moieties as potential bacterial NorA efflux pump inhibitors, the compound 1-[2-(5-nitro-1H-indol-2-yl)phenyl]methylpyridinium chloride (2) was synthesized and structurally characterized. This pyridinium chloride salt crystallized in the monoclinic space group P2(1)/c with the following unit cell dimensions: a 10.274(3) Å, b 13.101(4) Å, c 13.439(4) Å, b 107.702(7)°, V 1723.2(9) ų, Z (f.u.) = 4; R1 = 0.048, and wR2 = 0.13. Of interest in the single crystal X-ray structure is the (intramolecular) disposition of the pyridinium plane over the indole heterocyclic residue [interplanar dihedral angle 17.91(4)°].

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900865      PMCID: PMC6264680          DOI: 10.3390/molecules16097627

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Quaternary pyridinium salts are of continuing interest as biocidal agents [1,2,3,4] and we have synthesised one such salt as part of a broader project on new hybrid antibacterial agents incorporating 2-aryl-5-nitro-1H-indole moieties as bacterial NorA efflux pump inhibitors [5,6,7,8,9]. This pump in the human bacterial pathogen, Staphylococcus aureus, is known to compromise the activity of a range of antibacterials including biocidal quaternary salts and the quaternary alkaloid salt berberine [10]. In an attempt to introduce an N-tosyl protecting group into the nitro indolic pump inhibitor 1 [5], reaction with p-toluenesulfonyl chloride in the presence of pyridine as a base was investigated. This resulted, however, in the novel substituted pyridinium chloride salt 2, which was a potential hybrid antibacterial with an antibacterial benzylic pyridinium group (and potential NorA pump substrate) tethered to a NorA efflux pump blocking component. The synthesis and characterization of 2, together with a single crystal X-ray structure determination, is now reported in this paper.

2. Results and Discussion

The pyridinium salt 2 was synthesised from the previously described [5] indole alcohol 1 upon reaction with p-toluenesulfonyl chloride in the presence of pyridine followed by work up of the reaction mixture with exposure to hydrochloric acid (Scheme 1). The salt 2 was isolated in moderate yield and was characterized through spectroscopic data. The absence of any evidence for the presence of an aromatic methyl group (for the p-toluenesulfonyl functionality) was clear from the 1H- and 13C-NMR data, while the incorporation of a pyridinium moiety was indicated from the characteristic low field signals in the aromatic region of the 1H- and 13C-NMR spectra. Peak assignments in the latter spectrum were confirmed, where possible, through HMBC and HSQC experiments.
Scheme 1

Synthesis of the pyridinium salt 2.

The synthesis of 2 presumably proceeds through the intermediate p-toluenesulfonate derivative 1a, followed by nucleophilic displacement with pyridine [11] and then sulfonate/chloride exchange on the addition of concentrated HCl in the reaction work up (Scheme 1). The nucleophilic displacement would be expected to be facile at the benzylic site which is also activated through extended N-lone pair electron delocalisation. A single crystal X-ray study provided unequivocal structural confirmation for 2 including the presence of the chloride counterion (Table 1; Figure 1a). The compound is ionic and a single formula unit devoid of crystallographic symmetry comprises the asymmetric unit of the structure. The determination is nicely precise with non-hydrogen geometries being summarized in Table 2. The quaternary cation and its stereochemistry is depicted in Figure 1a, together with the associated chloride ion. Interestingly, the pyridinium ring plane lies over that of the heterocyclic component of the indole, C(2)…N(221) being only 2.930(2) Å (Figure 1b) possibly as a result of a favourable electronic interaction between the electron deficient pyridinium moiety and the electron rich fused pyrrolo ring in the indole; the other interatomic distances are more divergent with the two ring systems having an interplanar dihedral angle of 17.91(4)°. The substituent pattern introduces some irregular features into the C6 ring of the indole fragment: C(6)-C(7) is short (1.3749(15) Å) while C(3a)-C(7a) is long (1.4217(14) Å) with the angles at the opposed C(5,7a) enlarged (124.14(10), 122.70(9)°) and those at C(4,7) diminished (116.93(9), 117.69(9)°). At C(2) there is a gross asymmetry of ca. 10° in the exocyclic angles, despite the twist of the pendant aromatic ring plane (Table 2). The angle sum at the pyridinium nitrogen atom is 360.0°. The chloride ion has only one close contact: Cl...N,H(1) 3.0937(12), 2.28 Å (Cl…H(1)-N 154°), and is sufficiently close to the positive charge to be considered associated with the quaternized pyridinium nitrogen atom (Figure 1a), so that it resides in the lattice as an ion-pair. Crystal packing is dominated by inversion-related interactions between the planar residues, and diverse interspecies hydrogen contacts to other nitro and chloride components.
Table 1

Crystal data for compound 2.

FormulaC20H16ClN3O2
Fw365.8
Crystal systemMonoclinic
Space groupP21/c (#14)
a (Å)10.274(3)
b (Å)13.101(4)
c (Å)13.439(4)
β (°)107.702(7)
V3)1723.2(9)
Dc (g cm−3)1.410
Z (f.u.)4
μ (cm−1)2.4
Specimen (mm3)0.48 × 0.32 × 0.27
‘T’min/max0.92
Figure 1

Projection of the ion-pair of the pyridinium chloride salt 2 (a) through and (b) normal to the plane of the indole component, showing crystallographic numbering, and 50% probability amplitude displacement ellipsoids for the non-hydrogen atoms, with hydrogen atoms having arbitrary radii of 0.1 Å. Crystallographic numbering used is shown.

Table 2

Non-hydrogen interatomic distances (Å) and angles (°) for compound 2.

AtomsParameterAtomsParameter
Distances
N(1)-C(2)1.3859(13)C(21)-C(22)1.4050(16)
C(2)-C(3)1.3710(15)C(21)-C(26)1.3979(15)
C(3)-C(3a)1.4328(14)C(22)-C(23)1.3989(16)
C(3a)-C(4)1.3954(15)C(23)-C(24)1.388(2)
C(3a)-C(7a)1.4217(14)C(24)-C(25)1.381(2)
C(4)-C(5)1.3863(14)C(25)-C(26)1.391(2)
C(5)-N(5)1.4514(14)C(22)-C(220)1.5108(16)
C(5)-C(6)1.4028(15)C(220)-N(221)1.4898(14)
C(6)-C(7)1.3749(15)N(221)-C(222)1.3487(14)
C(7)-C(7a)1.3997(14)N(221)-C(226)1.3478(14)
N(1)-C(7a)1.3623(14)C(222)-C(223)1.374(2)
C(2)-C(21)1.4737(15)C(223)-C(224)1.388(2)
C(5)-N(5)1.4514(14)C(224)-C(225)1.387(2)
N(5)-O(51)1.2309(14)C(225)-C(226)1.380(2)
N(5)-O(52)1.2358(13)
Angles
C(2)-N(1)-C(7a)108.95(9)C(2)-C(21)-C(22)121.53(10)
N(1)-C(2)-C(3)109.46(9)C(2)-C(21)-C(26)119.37(10)
N(1)-C(2)-C(21)120.41(9)C(22)-C(21)-C(26)119.10(10)
C(3)-C(2)-C(21)130.02(9)C(21)-C(22)-C(23)118.93(10)
C(2)-C(3)-C(3a)107.05(9)C(21)-C(22)-C(220)123.79(9)
C(3)-C(3a)-C(4)134.46(9)C(23)-C(22)-C(220)117.24(10)
C(3)-C(3a)-C(7a)106.38(9)C(22)-C(23)-C(24)121.32(11)
C(4)-C(3a)-C(7a)119.03(9)C(23)-C(24)-C(25)119.65(11)
C(3a)-C(4)-C(5)116.93(9)C(24)-C(25)-C(26)119.91(11)
C(4)-C(5)-C(6)124.14(10)C(21)-C(26)-C(25)121.01(11)
C(4)-C(5)-N(5)118.52(9)C(22)-C(220)-N(221)114.44(9)
C(6)-C(5)-N(5)117.33(9)C(220)-N(221)-C(222)119.21(9)
C(5)-C(6)-C(7)119.35(9)C(220)-N(221)-C(226)119.58(9)
C(6)-C(7)-C(7a)117.69(9)C(222)-N(221)-C(226)121.17(9)
C(7)-C(7a)-N(1)129.17(9)N(221)-C(222)-C(223)120.53(11)
C(7)-C(7a)-C(3a)122.70(9)C(222)-C(223)-C(224)119.32(12)
N(1)-C(7a)-C(3a)108.11(9)C(223)-C(224)-C(225)119.41(12)
C(5)-N(5)-O(51)119.16(9)C(224)-C(225)-C(226)119.31(11)
C(5)-N(5)-O(52)118.41(10)N(221)-C(226)-C(225)120.26(11)
O(51)-N(5)-O(52)122.44(10)
Torsion angles (atoms denoted by number only, N italicized)
1-2-21-22−63.5(2)21-22-220-221−45.6(2)
2-21-22-2201.0(2)22-220-221-226−53.3(1)
A preliminary investigation of the antibacterial properties of compound 2 indicated it had only weak antibacterial activity against Staphylococcus aureus (K2361 strain overexpressing the NorA pump) and low pump inhibitory activity with respect to the antibacterial berberine in this mutant strain. In view of this weak activity, the synthesis of other related quaternary salt analogues was not pursued, although such analogues should be readily accessible via the same general route.

3. Experimental

3.1. General

The reaction was monitored by thin-layer chromatography (TLC) on Merck Silica gel 60 F254 with a thickness of 0.2 mm on an aluminium sheet, and the compounds were detected by examination under ultraviolet light and by exposure to iodine vapour. High resolution electron impact (EI+) MS was run using a VG Autospec spectrometer operating at 70 eV and a source temperature of 250 °C with PFK reference. The 1H- and 13C-NMR were determined at 299.92 and 75.42 MHz, respectively, with a Varian Unity-300 spectrometer. The melting point (mp) determination was recorded on a Reichert melting point apparatus and is reported uncorrected.

3.2. Synthesis of 1-[2-(5-Nitro-1H-indol-2-yl)phenyl]methylpyridinium Chloride (

To a solution of indole alcohol 1 (283.3 mg, 1.05 mmol) in dry pyridine (3 mL) was added p-toluenesulfonyl chloride (294.0 mg, 1.5 mmol) at 0 °C, and the mixture then stirred for 20 h. The resulting yellow suspension was poured into a mixture of 32% HCl (1.5 mL) in crushed ice (5 g), then filtered, and washed with H2O then Et2O. The yellow solid was dried to yield the indole pyridinium salt 2 (217.1 mg, 65.8%). Recrystallization from MeOH and DCM afforded the salt 2 as yellow prisms (44.3 mg), m.p. 231 °C (decomp.). 1H-NMR (CD3OD) δ 6.01 (s, 2H, CH2), 6.68 (s, 1H, H-3), 7.49 (br.d, J = 9 Hz, 1H, H-7), 7.58–7.64 (m, 4H, H-3′, H-4′, H-5′, H-6′ in the 2-aryl group), 7.82–7.87 (m, 2H, H-3″, H-5″ in the pyridine ring), 8.07 (dd, J = 9.1, 2.2 Hz, 1H, H-6), 8.40–8.50 (m, 1H, H-4″), 8.54 (dd, J = 2.2, 0.4 Hz, 1H, H-4), 8.60 (dd, J = 6.9, 1.2 Hz, 2H, H-2″, H-6″). 13C-NMR (CD3OD) δ 64.2 (CH2), 105.7 (C-3), 112.6 (C-7), 118.5 (C-6), 118.6 (C-4), 129.0 (C-3a), 129.1 (3C, ArCH), 131.1 (ArCH), 131.5 (ArCH), 132.1 (ArCH), 132.5 (ArCH), 133.1 (C-2), 134.1 (C-2′), 139.9 (C-7a), 141.1 (C-1′), 143.1 (C-5), 145.9 (ArCH), 147.1 (ArCH). HRMS (EI): m/z calcd for C20H16N3O2 [Quaternary ion]: 330.1243; found: 330.1251.

3.3. X-ray Structure Determination

A full sphere of CCD area-detector diffractometer data was measured on a pale-yellow prism (Bruker AXS instrument; ω-scans, 2θmax = 75°; monochromatic Mo Kα radiation, λ = 0.71073 Å; T ca. 150 K) yielding 34023 total reflections, these merging to 8384 unique after empirical/multiscan absorption correction (proprietary software; Rint = 0.026), and used in the full matrix least squares refinement, refining anisotropic displacement parameter forms for the non-hydrogen atoms, hydrogen atom treatment following a riding model, 6118 with I > 2σ(I) being considered ‘observed’. Reflection weights were: (σ2(F) + (0.0665P)2 + 0.482P)–1 (P = (F + 2F)/3). R1 was 0.048; wR2 0.13; S 1.03; |Δρmax| 0.54 e Å–3. Neutral atom complex scattering factors were employed within the SHELXL 97 program [12]. Pertinent results are given in Table 1 and Table 2, and Figure 1a and b.

4. Conclusions

The facile preparation of a novel indole-substituted benzylic pyridinium salt 2 is described and the salt characterized spectroscopically and through single crystal X-ray diffraction methodology. The solid state conformation of 2 indicated an interesting overlap of the pendant pyridinium ion and the indolic 5-membered ring.
  9 in total

1.  Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial.

Authors:  Anthony R Ball; Gabriele Casadei; Siritron Samosorn; John B Bremner; Frederick M Ausubel; Terence I Moy; Kim Lewis
Journal:  ACS Chem Biol       Date:  2006-10-24       Impact factor: 5.100

Review 2.  Efflux pumps as antimicrobial resistance mechanisms.

Authors:  Keith Poole
Journal:  Ann Med       Date:  2007       Impact factor: 4.709

3.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

4.  Synthesis of functionalized 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors.

Authors:  Siritron Samosorn; John B Bremner; Anthony Ball; Kim Lewis
Journal:  Bioorg Med Chem       Date:  2005-10-03       Impact factor: 3.641

5.  Synthesis of Berberine-Efflux Pump Inhibitor Hybrid Antibacterials.

Authors:  John B Bremner; Michael J Kelso
Journal:  Synth Commun       Date:  2010-01-01       Impact factor: 2.007

6.  Synthesis, structure and in vitro antibacterial activities of new hybrid disinfectants quaternary ammonium compounds: pyridinium and quinolinium stilbene benzenesulfonates.

Authors:  Kullapa Chanawanno; Suchada Chantrapromma; Theerasak Anantapong; Akkharawit Kanjana-Opas; Hoong-Kun Fun
Journal:  Eur J Med Chem       Date:  2010-06-17       Impact factor: 6.514

7.  Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components.

Authors:  Danuta Tomkiewicz; Gabriele Casadei; Jonah Larkins-Ford; Terence I Moy; James Garner; John B Bremner; Frederick M Ausubel; Kim Lewis; Michael J Kelso
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

8.  Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group.

Authors:  Siritron Samosorn; Bongkot Tanwirat; Nussara Muhamad; Gabriele Casadei; Danuta Tomkiewicz; Kim Lewis; Apichart Suksamrarn; Therdsak Prammananan; Karina C Gornall; Jennifer L Beck; John B Bremner
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

9.  Synthesis and antimicrobial activity of some pyridinium salts.

Authors:  Vildan Alptüzün; Sülünay Parlar; Hüseyin Taşli; Ercin Erciyas
Journal:  Molecules       Date:  2009-12-14       Impact factor: 4.411

  9 in total
  1 in total

1.  Synthesis and crystal structure of a new pyridinium bromide salt: 4-methyl-1-(3-phen-oxy-prop-yl)pyridinium bromide.

Authors:  Musa A Said; Mohamed R Aouad; David L Hughes; Meshal A Almehmadi; Mouslim Messali
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.